Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 2Recurrence 1Multiple Myeloma 1Gliosarcoma 1Glioma 1Ependymoma 1Disease Progression 1Brain Neoplasms 1

Interventions

Temozolomide 7Magnetic Resonance Spectroscopy 7X-Rays 5Phantoms, Imaging 5Bevacizumab 5Specimen Handling 4Nuclear Medicine Department, Hospital 4Carboplatin 3Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2Vemurafenib 2Lapatinib 2LY3023414 2Everolimus 2Etoposide 2Erlotinib Hydrochloride 2veliparib 1pomalidomide 1poly ICLC 1picropodophyllin 1marizomib 1imetelstat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Ependymoma × marizomib × Clear all
NCT03727841 2022-07-27

Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
4 enrolled 13 charts

Ependymoma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡